What Is Mycoplasma Hominis? Causes, Symptoms & Treatment

Mycoplasma hominis is a tiny bacterium that lives in the human urogenital tract, often without causing any symptoms at all. It was first isolated from the human genital tract in 1937, making it one of the earliest-discovered human mycoplasmas, and it remains one of the most common genital mycoplasmas found in adults today.¹ What makes it unusual compared to most bacteria you hear about is that it lacks a cell wall entirely, which has big implications for how it behaves, what symptoms it causes, and which antibiotics work against it.

A Bacterium Without a Cell Wall

Mycoplasmas belong to a class called Mollicutes, which literally translates to “soft skin.” Unlike most bacteria, M. hominis has no rigid cell wall surrounding its membrane. That missing wall is the reason many common antibiotics, including penicillins and cephalosporins, are completely useless against it. Those drugs work by disrupting cell-wall construction, and you cannot disrupt something that does not exist.

M. hominis is also unusual in how it fuels itself. Rather than breaking down sugars the way many bacteria do, it generates energy by degrading the amino acid arginine through a dedicated set of enzymes.² This arginine-based metabolism is part of what makes M. hominis a slow grower and contributes to its ability to persist in human tissue for long stretches without triggering an obvious immune response.³ Among the genital mycoplasmas, M. hominis is the one most commonly linked to infections that spread beyond the reproductive tract.

How Common Is Colonization

A lot of people carry M. hominis without ever knowing it. In sexually mature women, estimates suggest it can be found in the vagina or cervix of roughly 20 to 50 percent, depending on the population studied.¹ Those numbers vary widely by geography and the testing method used. An Italian multicenter study using molecular testing found a cervical colonization rate of about 9 percent among women of childbearing age, with symptomatic women testing positive at significantly higher rates than asymptomatic controls.⁴ A study in India using a sensitive PCR method found M. hominis in 20 percent of women attending outpatient clinics, though many carried it without symptoms.⁵

Men carry M. hominis far less often. A large Korean study testing nearly 5,000 female and about 1,000 male specimens found M. hominis in under 1 percent of women (by culture alone) and did not identify any M. hominis colonization in males at all.⁶ South Korean data across a much larger testing pool did find M. hominis in men, but at lower rates than in women: about 4.5 percent in men versus about 9 percent in women.⁷ The rates were highest in younger adults under 30, declining with age.

How M. Hominis Spreads

Sexual contact is the primary route of transmission in adults. The more sexual partners a person has, the more likely they are to carry M. hominis, which is why colonization rates are higher in sexually active populations and lower in those who have not yet been sexually active. Vertical transmission, from mother to baby during delivery, is the other major route and the one responsible for neonatal infections.⁸ There is no evidence that casual contact, sharing towels, or using public toilets spreads the organism.

Symptoms in Women

Most women who carry M. hominis never develop symptoms. When the organism does cause disease, the infections it is most strongly linked to include bacterial vaginosis, pelvic inflammatory disease (PID), and cervicitis. M. hominis tends to thrive in the disrupted vaginal environment seen in bacterial vaginosis, and the two are frequently found together. PID, which involves inflammation of the uterus, fallopian tubes, or surrounding tissue, can cause pelvic pain, fever, and abnormal vaginal discharge. M. hominis has also been associated with infertility, though teasing apart its independent contribution from other coexisting infections remains difficult.⁹

Symptoms in Men

The role of M. hominis in male urogenital disease is considerably murkier. While Mycoplasma genitalium is well-established as a cause of non-gonococcal urethritis in men, the evidence for M. hominis playing the same role is weak. A review in Sexually Transmitted Infections concluded there is no clear evidence supporting M. hominis as a cause of urethritis, though it noted it would be unwise to dismiss the organism entirely given its known ability to cause disease elsewhere.¹⁰ In one study of 390 men with urethritis, only 4 (about 1 percent) carried M. hominis, compared to about 15 percent who had Ureaplasma urealyticum.¹¹

That said, when M. hominis is found alongside symptoms such as urethral discharge, painful urination, or prostatitis and no other pathogen is detected, clinicians sometimes treat it. The challenge is distinguishing innocent bystander colonization from genuine infection. A positive test result in a man with urethritis does not prove M. hominis is the culprit.

Pregnancy and Neonatal Risks

Pregnancy is where M. hominis gets the most clinical attention. In women with threatened preterm labor, vaginal colonization with M. hominis or Ureaplasma urealyticum has been linked to a substantially higher rate of preterm delivery. One study found preterm birth in 53 percent of women who tested positive for these organisms, compared to 25 percent in the negative group, with an adjusted odds ratio of 4.0 for preterm birth before 37 weeks.¹² Co-infection with both organisms appears to be worse than either alone, resulting in lower birth weights, earlier deliveries, and more frequent admissions to neonatal intensive care.¹³

M. hominis can also infect the placental membranes, causing chorioamnionitis, an inflammation of the fetal membranes that is a recognized trigger for premature rupture of membranes and early delivery. A recent case report confirmed M. hominis as the cause of chorioamnionitis following preterm premature rupture of membranes, though the authors noted it remains unclear whether targeted antibiotic therapy during pregnancy can actually prevent these complications.¹⁴

Newborns who pick up M. hominis during delivery can develop serious infections. The organism’s ability to cause pneumonia, bloodstream infection, and meningitis in neonates is well documented.¹⁵ Neonatal meningitis from M. hominis is rare but carries severe consequences, particularly in extremely preterm infants. Case reports describe babies presenting with lethargy, rapid heart rate, and seizures in the first week of life, and because standard cultures often miss mycoplasmas, diagnosis can be delayed.¹⁶

Infections Outside the Reproductive Tract

Although M. hominis lives primarily in the urogenital area, it is the genital mycoplasma most frequently reported in systemic infections.³ These extragenital infections tend to occur in people whose immune systems are compromised or who have recently undergone surgery. A classic review found that most patients with extragenital M. hominis infections had prior surgery at or near the infection site, and the organism was isolated from blood, cerebrospinal fluid, pleural fluid, joint fluid, and bone.¹⁷

Sternal wound infections after cardiac surgery are a recurring theme in the case literature. Because M. hominis does not grow on standard bacterial culture media and is invisible on a Gram stain (no cell wall, remember), surgeons sometimes face a baffling scenario: an infected wound that shows plenty of white blood cells but no visible bacteria, and that fails to respond to the usual post-surgical antibiotics. A recent case report and review flagged exactly this pattern, urging clinicians to suspect M. hominis when wound cultures are negative despite obvious signs of infection and when standard antibiotics are not working.¹⁸ Another case series described three patients who developed deep sternal wound infections after cardiac surgery, all presenting with fever and clear exudate from the wound, who improved significantly after surgical debridement combined with fluoroquinolone antibiotics for more than two weeks.¹⁹

Joint infections are another well-documented site. M. hominis has caused septic arthritis of native joints, particularly in people with weakened immune defenses. One reported case involved a young patient on immunosuppressive therapy who developed septic arthritis of the hip with a deep abscess, with delayed diagnosis due to the difficulty of identifying the organism on routine testing.²⁰

How It Evades the Immune System

One reason M. hominis can persist for so long in the body without being cleared is its suite of immune evasion tactics. Mycoplasmas in general are skilled at dodging host defenses. They produce enzymes that break down reactive oxygen molecules and other antimicrobial substances released by immune cells. They can form biofilms, which are structured communities of bacteria embedded in a protective matrix that makes them harder to reach for both antibiotics and the immune system. M. hominis and related species also engage in antigen variation, regularly changing the proteins displayed on their surface so the immune system has trouble recognizing them.²¹ Some mycoplasmas also use molecular mimicry, displaying molecules that look enough like host tissue to avoid triggering an alarm.²²

The Trichomonas Connection

One of the stranger aspects of M. hominis biology is its relationship with Trichomonas vaginalis, the protozoan parasite responsible for trichomoniasis. M. hominis can live inside T. vaginalis cells as an endosymbiont, meaning one pathogen physically resides inside another. This is the only known symbiosis between two obligate human mucosal pathogens that can independently cause disease at the same body site.²³ Research has shown that this partnership benefits both organisms: M. hominis can modulate the parasite’s behavior, influencing its growth rate, its ability to damage host cells, and the inflammatory response it provokes.²⁴ This means that when a patient has trichomoniasis, M. hominis may be along for the ride, potentially amplifying symptoms and inflammation while hiding from treatment inside the parasite.

Diagnosis

Detecting M. hominis is trickier than testing for most bacteria. It does not grow on the routine culture media used in most hospital labs, and because it has no cell wall, it does not stain with the standard Gram stain technique. Special culture media exist, but even then, M. hominis grows slowly compared to common pathogens. PCR-based molecular testing has become the preferred method because it is faster and more sensitive than culture. One head-to-head comparison found that real-time PCR targeting the yidC gene detected M. hominis in 55 out of 153 urogenital specimens, versus only 45 by culture, confirming the molecular approach picks up cases that culture misses.²⁵ Multiplex PCR assays that test for M. hominis alongside Ureaplasma species in a single run are now widely available and offer both high sensitivity and rapid turnaround.²⁶

The diagnostic difficulty cuts both ways. The fact that routine cultures miss M. hominis means some genuine infections go unrecognized, as in the post-surgical scenarios described above. But the high sensitivity of PCR also means it will pick up harmless colonization. A positive PCR result in someone without symptoms does not mean that person has a disease that needs treating.

Should You Get Tested

This is a point where the evidence firmly pushes back against the impulse to test for everything. A position statement from the European STI Guidelines Editorial Board concluded that there is currently no evidence that routine testing and treating M. hominis does more good than harm. The board recommended against routine screening of asymptomatic men and women and against routine testing even of symptomatic individuals for M. hominis.²⁷ Their reasoning: asymptomatic carriage is so common that a positive test often tells you nothing actionable, and treating colonization with antibiotics contributes to resistance without clear benefit to the patient.

Testing makes more sense in specific clinical situations: unexplained pelvic inflammatory disease that has not responded to standard treatment, culture-negative post-surgical wound infections in patients on standard antibiotics, suspected neonatal meningitis with negative routine cultures, or investigation of recurrent preterm birth. Outside of those contexts, a positive M. hominis result is more likely to create anxiety and unnecessary antibiotic use than to lead to a meaningful intervention.

Treatment and Antibiotic Resistance

When M. hominis does need to be treated, the antibiotic options are limited from the start. Because it has no cell wall, all beta-lactam antibiotics (penicillins, cephalosporins, carbapenems) are ineffective. On top of that, M. hominis is intrinsically resistant to the 14- and 15-membered macrolides, a group that includes erythromycin and azithromycin. This resistance stems from specific mutations in its ribosomal RNA that reduce how tightly these drugs bind to their target, combined with an active efflux pump that pushes the drug back out of the cell.²⁸ This is a critical point because azithromycin is a go-to drug for many sexually transmitted infections and for Mycoplasma genitalium specifically, but it is useless against M. hominis.

The antibiotics that do work against M. hominis include tetracyclines (doxycycline is the most commonly prescribed) and fluoroquinolones (such as moxifloxacin and levofloxacin). Clindamycin is another option that retains activity. However, acquired resistance is an emerging concern. A French study spanning five years found that all tetracycline-resistant M. hominis isolates carried the tet(M) resistance gene, and fluoroquinolone-resistant isolates harbored mutations in genes encoding their drug targets. Isolates resistant to both levofloxacin and moxifloxacin carried mutations in multiple genes simultaneously.²⁹

In practice, doxycycline remains the first-line choice for most M. hominis infections. For cases where doxycycline fails or resistance is suspected, fluoroquinolones are the backup. The post-cardiac surgery cases mentioned earlier responded well to fluoroquinolone treatment sustained for at least two weeks, often combined with surgical debridement of infected tissue.¹⁹ For neonatal infections, treatment decisions are more complex because of the limited safety data on many of these antibiotics in very young infants.

How M. Hominis Differs from Mycoplasma Genitalium

People often encounter “mycoplasma” as a diagnosis without clarity about which species is involved, and the distinction matters. Mycoplasma genitalium is a well-recognized cause of urethritis in men and cervicitis in women, and it has a strong evidence base linking it to sexually transmitted disease. M. hominis, by contrast, is more of an opportunist: it colonizes widely, rarely causes disease on its own in healthy adults, and its strongest clinical associations are with conditions like bacterial vaginosis, post-surgical infections, and pregnancy complications rather than classic STI presentations.

The treatment difference is equally important. M. genitalium is typically treated with azithromycin or moxifloxacin, while M. hominis is intrinsically resistant to azithromycin. A treatment plan that works for one species may fail completely for the other. M. genitalium was also significantly harder to grow in the lab historically, requiring PCR for most clinical studies, whereas M. hominis, though slow, can be cultured on special media.¹ If you are told you have a “mycoplasma infection,” it is worth asking which species, because the implications and the appropriate antibiotic are different.

Who Is Most at Risk for Serious Infection

For the vast majority of people who carry M. hominis, it will never cause a problem. Serious infection tends to cluster in a few groups:

Immunosuppressed patients: people on drugs that dampen the immune system, such as organ transplant recipients or those receiving certain cancer therapies, face the highest risk of M. hominis spreading to joints, the bloodstream, or surgical sites.²⁰
Post-surgical patients: particularly after cardiothoracic and organ transplant surgery, where M. hominis can infect sternal wounds, the mediastinum, or transplanted organs.¹⁸
Pregnant women: especially those already at risk for preterm labor or premature rupture of membranes.
Premature newborns: whose immature immune systems make them vulnerable to meningitis and bloodstream infections acquired during delivery.¹⁵

Healthy, non-pregnant adults with intact immune systems who happen to carry M. hominis are unlikely to need treatment. The organism is a genuine pathogen in certain contexts, but it is a commensal bystander in many more. The biggest practical risk for most people is not M. hominis itself but the unnecessary antibiotics prescribed after a positive test in someone who does not actually have a disease.